Business Context and Reporting Period
PDS Biotechnology Corporation (PDSB) filed a Form 8-K on April 22, 2025, reporting a corporate governance event. The company is incorporated in Delaware and trades on the Nasdaq Capital Market.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a personnel change.
Material Changes
The material change reported is the departure of Sir Richard Sykes from the Board of Directors. He notified the company on April 22, 2025, that he will retire and not stand for re-election upon the expiration of his current term at the 2025 Annual Meeting of Stockholders.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, risks, contingencies, or unusual items. The report is limited to the notification of the director's retirement.
Key Facts for Investors
- Sir Richard Sykes is retiring from the Board of Directors.
- His term expires at the 2025 Annual Meeting of Stockholders.
- He will not stand for re-election.
- The filing was signed by Frank Bedu-Addo, Ph.D., President and CEO, on April 24, 2025.